LON:INDV - Indivior Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: GBX 325
  • Forecasted Upside: 0.87 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 1 Buy Ratings
  • 0 Strong Buy Ratings
GBX 322.20
▲ +6.4 (2.03%)

This chart shows the closing price for INDV by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Indivior Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for INDV and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for INDV

Analyst Price Target is GBX 325
▲ +0.87% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Indivior in the last 3 months. The average price target is GBX 325, with a high forecast of GBX 0 and a low forecast of GBX 0. The average price target represents a 0.87% upside from the last price of GBX 322.20.

This chart shows the closing price for INDV for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Indivior. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/4/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2021
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/27/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/28/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/28/2022

Latest Recommendations

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
3/25/2022Morgan StanleyInitiated CoverageEqual WeightGBX 330
6/30/2021Numis SecuritiesReiterated RatingBuyGBX 320
1/28/2021Jefferies Financial GroupReiterated RatingBuyGBX 205
1/26/2021CitigroupReiterated RatingBuyGBX 185
1/19/2021Jefferies Financial GroupReiterated RatingBuyGBX 180
7/27/2020Jefferies Financial GroupUpgradeBuyGBX 70 ➝ GBX 200
7/22/2020CitigroupBoost Price TargetNeutralGBX 45 ➝ GBX 85
6/30/2020Jefferies Financial GroupReiterated RatingHold
6/17/2020Jefferies Financial GroupBoost Price TargetHoldGBX 39 ➝ GBX 70
2/25/2020CitigroupLower Price TargetNeutralGBX 58 ➝ GBX 45
1/21/2020Jefferies Financial GroupLower Price TargetHoldGBX 65 ➝ GBX 39
11/15/2019Jefferies Financial GroupReiterated RatingHold
11/7/2019CitigroupReiterated RatingNeutral
5/2/2019CitigroupReiterated RatingNeutralGBX 150
4/10/2019Royal Bank of CanadaReiterated RatingSector PerformGBX 130
4/10/2019Numis SecuritiesReiterated RatingBuy
2/18/2019Jefferies Financial GroupDowngradeHoldGBX 118 ➝ GBX 114
2/5/2019Numis SecuritiesReiterated RatingBuy
12/18/2018Numis SecuritiesReiterated RatingBuyGBX 180
12/12/2018Royal Bank of CanadaDowngradeSector Performer
11/21/2018Royal Bank of CanadaDowngradeOutperformGBX 350 ➝ GBX 130
11/2/2018Royal Bank of CanadaReiterated RatingOutperformGBX 350
10/15/2018CitigroupReiterated RatingNeutral
10/11/2018Jefferies Financial GroupLower Price TargetBuyGBX 250 ➝ GBX 245
9/27/2018Numis SecuritiesReiterated RatingBuyGBX 350
7/26/2018CitigroupLower Price TargetNeutralGBX 365 ➝ GBX 350
7/25/2018Numis SecuritiesUpgradeBuyGBX 380
7/25/2018Jefferies Financial GroupReiterated RatingBuy
7/17/2018CitigroupLower Price TargetNeutralGBX 500 ➝ GBX 365
7/11/2018Jefferies Financial GroupReiterated RatingBuyGBX 630 ➝ GBX 545
7/11/2018Numis SecuritiesDowngradeHold
6/19/2018Morgan StanleyLower Price TargetEqual weightGBX 455 ➝ GBX 398
6/15/2018Jefferies Financial GroupReiterated RatingBuyGBX 630
6/15/2018Royal Bank of CanadaReiterated RatingOutperformGBX 540 ➝ GBX 550
6/15/2018Numis SecuritiesReiterated RatingBuy
5/15/2018CitigroupDowngradeNeutralGBX 490 ➝ GBX 500
5/8/2018Jefferies Financial GroupBoost Price TargetBuyGBX 610 ➝ GBX 630
5/2/2018Numis SecuritiesReiterated RatingBuyGBX 600
4/9/2018Jefferies Financial GroupBoost Price TargetBuyGBX 500 ➝ GBX 610
4/3/2018Morgan StanleyBoost Price TargetEqual weightGBX 450 ➝ GBX 455
3/23/2018Royal Bank of CanadaReiterated RatingOutperformGBX 540
3/23/2018Numis SecuritiesReiterated RatingBuyGBX 600
3/16/2018Numis SecuritiesReiterated RatingBuyGBX 640
2/15/2018Numis SecuritiesReiterated RatingBuyGBX 640
1/26/2018Royal Bank of CanadaBoost Price TargetOutperformGBX 500 ➝ GBX 540
1/22/2018Numis SecuritiesReiterated RatingBuyGBX 640
1/17/2018Jefferies Financial GroupReiterated RatingBuyGBX 500
12/1/2017Royal Bank of CanadaReiterated RatingOutperformGBX 500
12/1/2017Morgan StanleyReiterated RatingEqual weightGBX 410
11/30/2017Numis SecuritiesReiterated RatingBuyGBX 640
11/9/2017Morgan StanleyBoost Price TargetEqual WeightGBX 320 ➝ GBX 410
11/9/2017Jefferies Financial GroupBoost Price TargetBuyGBX 358 ➝ GBX 472
11/8/2017CitigroupUpgradeBuyGBX 280 ➝ GBX 490
10/30/2017Numis SecuritiesReiterated RatingBuyGBX 500
10/26/2017CitigroupReiterated RatingNeutralGBX 280
10/20/2017Numis SecuritiesReiterated RatingBuyGBX 500
9/15/2017Numis SecuritiesReiterated RatingBuyGBX 470
9/15/2017Stifel NicolausReiterated RatingBuyGBX 400
9/8/2017Jefferies Financial GroupLower Price TargetBuyGBX 540 ➝ GBX 358
9/5/2017CitigroupReiterated RatingNeutralGBX 280
9/1/2017Numis SecuritiesReiterated RatingBuyGBX 470
8/11/2017Jefferies Financial GroupBoost Price TargetBuyGBX 490 ➝ GBX 540
8/3/2017Royal Bank of CanadaReiterated RatingOutperformGBX 470
7/28/2017Royal Bank of CanadaUpgradeOutperformGBX 390 ➝ GBX 470
7/27/2017Numis SecuritiesReiterated RatingBuyGBX 490
7/11/2017Numis SecuritiesReiterated RatingBuyGBX 490
6/7/2017Jefferies Financial GroupReiterated RatingBuyGBX 490
5/31/2017Numis SecuritiesReiterated RatingBuyGBX 490
(Data available from 5/28/2017 forward)

News Sentiment Rating

0.35 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 8 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/30/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/29/2021
  • 2 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/29/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
1/28/2022
  • 1 very positive mentions
  • 11 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
2/27/2022
  • 0 very positive mentions
  • 8 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/29/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
4/28/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/28/2022

Current Sentiment

  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Indivior logo
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders. The company's product pipeline focuses on treating opioid use disorder, addiction, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC has research collaboration agreement with Addex Therapeutics Ltd. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
Read More

Today's Range

Now: GBX 322.20
Low: 314.80
High: 323.40

50 Day Range

MA: GBX 304.80
Low: 269
High: 335.45

52 Week Range

Now: GBX 322.20
Low: 143.60
High: 340

Volume

610,139 shs

Average Volume

1,670,506 shs

Market Capitalization

£2.27 billion

P/E Ratio

17.51

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Indivior?

The following Wall Street research analysts have issued reports on Indivior in the last twelve months: Morgan Stanley, and Numis Securities Ltd.
View the latest analyst ratings for INDV.

What is the current price target for Indivior?

0 Wall Street analysts have set twelve-month price targets for Indivior in the last year. Their average twelve-month price target is GBX 325, suggesting a possible upside of 1.4%.
View the latest price targets for INDV.

What is the current consensus analyst rating for Indivior?

Indivior currently has 1 hold rating and 1 buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe INDV will outperform the market and that investors should add to their positions of Indivior.
View the latest ratings for INDV.

How do I contact Indivior's investor relations team?

Indivior's physical mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The specialty pharmaceutical company's listed phone number is +44-1753-217800. The official website for Indivior is indivior.com. Learn More about contacing Indivior investor relations.